Sands Capital led a $100m Series D round in Cytovale.

Sands Capital, a venture capital firm, led a $100m Series D round in Cytovale, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, with participation from Canada Pension Plan Investment Board, Norwest Venture Partners, Global Health Investment Corporation and Breakout Ventures. "Sepsis is the largest single condition presenting to the Emergency Department where there hasn't been an effective diagnostic to quickly and effectively triage patients. Cytovale's IntelliSep test has now been demonstrated, prospectively, to help save lives and money by doing just that. We're excited to lead this financing and help accelerate Cytovale's commercial launch," Parker Cassidy, Sands Capital Partner.